<표1> 2003년 신약개발 프로젝트 수 기준 상위 25개 제약기업

(단위: 수)

순위 2003(2002)	회사명	신약개발 프로젝트수 2003(2002)	자체 신약개발수
1(1)	GSK	190(176)	112
2(8)	Haffmann-La Roche	139(93)	78
3(4)	Johnson&Johnson	123(103)	60
4(2)	Aventis	122(123)	70
5(5)	Pfizer	97(98)	54
6(8)	AstraZeneca	92(83)	60
7(16)	Novartis	87(67)	54
8(9)	Merck&Co	81(82)	53
9(10)	Schering AG	80(82)	53
10(3)	Abbott	80(119)	80
11(12)	Wyeth	77(81)	49
12(7)	Elan	75(88)	29
13(15)	Sanofi-Synthelabo	73(68)	56
14(14)	Pharmacia	71(69)	40
15(11)	Bristol-Myers Squibb	70(82)	44
16(18)	Eli Lilly	65(60)	32
17(13)	Bayer	58(77)	43
18(17)	Schering-Plough	56(60)	30
19(20)	Genzyme	53(47)	41
20(21)	Shire	48(47)	29
21(19)	Merck KGaA	46(52)	27
22(24)	Millennium	44(42)	34
23(35)	Akzo Nobel	43(34)	32
24(37)	Daiichi Pharmaceutical	43(32)	26
25(34)	Yamanouchi	42(35)	24

※ 자료: Pharmaprojects Annual Review 2003

<표2> 2003년 치료영역별 신약 연구분야 순위

(단위: 수)

순위 2003(2002)	약효군(code)	제품수 2003(2002)
1(1)	Anticancer, other(K6Z)	932(870)
2(2)	Anticancer, immunological(K3)	517(433)
3(4)	Cardiovascular(C9Z)	336(317)
4(5)	Prophyactic vaccine(J7A1)	321(298)
5(6)	Antiasthma(R8A)	289(270)
6(3)	Gene therapy(T4A)	286(321)
7(11)	Analgesic, other(N3Z)	280(231)
8(7)	Antidiabetic(A10B)	272(259)
9(8)	Neuroprotective(N7C)	268(254)
10(10)	Antiviral, other(J5Z)	237(236)
11(12)	Anti-inflammatory(M1A1)	235(217)
12(15)	Recombinant, other(T2Z)	223(184)
13(13)	Cognition enhancer(N6D)	222(203)
14(14)	Immunosuppressive(I5)	211(201)
15(18)	GI Inflammatory bowel Disorders(A16)	209(175)
16(16)	Antiviral, anti-HIV(J5A)	193(182)
17(21)	Formulation technology(F7Z)	185(152)
18(19)	Recombinants, other(T2Z)	175(157)
19(17)	GEnomics technology(T4C)	174(181)
20(20)	Antiarthritic, other(M2Z)	163(152)
21(25)	Ophthalmological(S1Z)	157(137)
22(22)	Neurological(N11Z)	154(145)
23(24)	Antidepressant(N10A)	143(142)
24(27)	Urological(G4Z)	142(127)
25(39)	Monoclonal antibody, other(T3A9)	140(101)

※ 자료: Pharmaprojects Annual Review 2003